3-环戊氧基-4-甲氧基苯甲酸 | 144036-17-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-环戊氧基-4-甲氧基苯甲酸
• 中文别名: 3-环戊基氧基-4-甲氧基苯甲酸
• 英文名称: 3-cyclopentyloxy-4-methoxy benzoic acid
• 英文别名: 3-(cyclopentyloxy)-4-methoxy-benzoic acid；3-(cyclopentyloxy)-4-methoxybenzoic acid；3-cyclopentyloxy-4-methoxybenzoic acid；4-methoxy-3-cyclopentyloxybenzoIc acid
• CAS: 144036-17-9
• 化学式: C₁₃H₁₆O₄
• mdl: MFCD00219797
• 分子量: 236.268
• InChiKey: RVADCQWIQKYXBJ-UHFFFAOYSA-N

物化性质

• 熔点：
  160-164°C
• 沸点：
  376.3±22.0 °C(Predicted)
• 密度：
  1.213±0.06 g/cm3 (20 ºC 760 Torr)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2918990090
• 储存条件：
  室温

SDS

Name:	3-(Cyclopentyloxy)-4-methoxybenzoic acid 97% Material Safety Data Sheet
Synonym:
CAS:	144036-17-9

Section 1 - Chemical Product MSDS Name:3-(Cyclopentyloxy)-4-methoxybenzoic acid 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
144036-17-9	3-(Cyclopentyloxy)-4-methoxybenzoic ac	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 144036-17-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 160 - 164 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C13H16O4
Molecular Weight: 236

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, bases, acid chlorides, halogenated agents, halogens.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 144036-17-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-(Cyclopentyloxy)-4-methoxybenzoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 144036-17-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 144036-17-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 144036-17-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-环戊氧基-4-甲氧基苯甲酸 在 氯化亚砜 、 potassium tert-butylate 、 N,N-二甲基甲酰胺 作用下， 以 甲苯 为溶剂， 反应 3.5h， 生成 吡拉米司特
  参考文献：
  名称：

  Cook, David C.; Jones, Ronald H.; Kabir, Humayun, Organic Process Research and Development, 1998, vol. 2, # 3, p. 157 - 168

  摘要：

  DOI：
• 作为产物：
  描述：

  3-环戊氧-4-甲氧基苯甲醛 在 双氧水 、 sodium hydroxide 、 zinc(II) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 40.0h， 以53%的产率得到3-环戊氧基-4-甲氧基苯甲酸
  参考文献：
  名称：

  人环核苷酸磷酸二酯酶4B2全长和152〜528截短的比较用于表征抑制剂。

  摘要：

  目的和目的作为筛选和表征抑制剂目标的人类全长环状核苷酸磷酸二酯酶同工酶4B2（hPDE4B2）的活性收率低，并且两个构象态对（R）-咯利普兰的亲和力并存。因此，将仅以（R）-咯利普兰的低亲和力构象状态存在的hPDE4B2的152〜528截短与全长hPDE4B2进行比较以表征抑制剂。材料和方法在N端带有6His-SUMO标签的全长hPDE 4B2（SF-hPDE4B2）和152〜528截短体（ST-hPDE4B2）在大肠杆菌细胞中表达，通过Ni-NTA柱纯化并比较了抑制剂的特性。通过单磷酸酶对AMP的偶联作用和用孔雀石绿分光光度法测定磷酸盐，用96孔微孔板测定了一些合成的咯利普兰类似物对两个靶的抑制常数（Ki）。结果用Ni2 + -NTA柱进行亲和纯化后，ST-hPDE4B2的比活度比SF-hPDE4B2高约30倍，活性产率高出100倍。ST-hPDE4B2上的（R）-咯利普兰的Ki与在昆虫

  DOI：

  10.2174/1386207322666190306142810
• 作为试剂：
  描述：

  3-环戊氧-4-甲氧基苯甲醛 、 3-环戊氧基-4-甲氧基苯甲酸 在 3-环戊氧基-4-甲氧基苯甲酸 作用下， 以5的产率得到N6-(3-碘苄基)腺苷-5'-N-甲基糖酰胺
  参考文献：
  名称：

  J. Med. Chem. 1986, 29, 1683-1689

  摘要：

  DOI：

文献信息

• Compounds containing phenyl linked to aryl or heteroaryl by an
  申请人：Rhone-Poulenc Rorer Limited

  公开号：US05935978A1

  公开（公告）日：1999-08-10

  This invention is directed to the pharmaceutical use of phenyl compounds, which are linked to an aryl moiety by various linkages, for inhibiting tumor necrosis factor. The invention is also directed to the compounds, their preparation and pharmaceutical compositions containing these compounds. Furthermore, this invention is directed to the pharmaceutical use of the compounds for inhibiting cyclic AMP phosphodiesterase.

  这项发明涉及苯基化合物的药用，这些化合物通过各种连接与芳基团相连，用于抑制肿瘤坏死因子。该发明还涉及这些化合物、它们的制备以及含有这些化合物的药物组合物。此外，这项发明还涉及这些化合物的药用，用于抑制环磷酸腺苷磷酸二酯酶。
• Amine Compounds
  申请人：Ohmori Yutaka

  公开号：US20080200535A1

  公开（公告）日：2008-08-21

  There is provided a compound exhibiting an activity of suppressing immune response with reduced adverse drug reactions, which compound is useful in the chemotherapy for preventing or treating, for example, a wide range of various autoimmune diseases including systemic erythematodes, chronic rheumatoid arthritis, Type I diabetes, inflammatory bowel disease, biliary cirrhosis, uveitis, multiple sclerosis or other disorders, or chronic inflammatory diseases, or cancers, lymphoma or leukemia, or resistance to organ or tissue transplantation or rejection against transplantation. Novel amine compounds having an S1P1/Edg1 receptor agonist effect, possible stereoisomers or racemic bodies of the compounds, or pharmacologically acceptable salts, hydrates or solvates of the compound, the stereoisomers or the racemic bodies, or prodrugs of the compounds, the stereoisomers, the racemic bodies, the salts, the hydrates or the solvates, are provided.

  提供了一种化合物，具有抑制免疫反应并减少不良药物反应的活性，该化合物在化疗中用于预防或治疗各种自身免疫性疾病，包括系统性红斑狼疮、慢性类风湿关节炎、I型糖尿病、炎症性肠病、胆汁性肝硬化、葡萄膜炎、多发性硬化或其他疾病，慢性炎症性疾病，癌症，淋巴瘤或白血病，器官或组织移植的抗性或对移植的排斥。提供了具有S1P1/Edg1受体激动剂作用的新型胺类化合物，可能是这些化合物的立体异构体或消旋体，或这些化合物、立体异构体或消旋体的药理学上可接受的盐、水合物或溶剂合物，或这些化合物、立体异构体、消旋体、盐、水合物或溶剂的前药。
• Synthesis and evaluation of clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of Alzheimer's disease
  作者：Jinhui Hu、Tingting Pan、Baijiao An、Zhengcunxiao Li、Xingshu Li、Ling Huang

  DOI：10.1016/j.ejmech.2018.12.013

  日期：2019.2

  Considering the importance of PDE4D inhibition and the modulation of biometals in Alzheimer's disease (AD) therapeutics, we have designed, synthesized and evaluated a series of new clioquinol-rolipram/roflumilast hybrids as multitarget-directed ligands for the treatment of AD. In vitro studies demonstrated that some of the molecules processed remarkable inhibitory activity against phosphodiesterase

  考虑到PDE4D抑制和生物金属在阿尔茨海默氏病（AD）疗法中的重要性，我们设计，合成和评估了一系列新的氯喹诺醇-咯利普兰/鲁氟司特杂合体，作为多靶点定向配体用于AD治疗。体外研究表明，某些分子对磷酸二酯酶4D（PDE4D）具有显着的抑制活性，强大的细胞内抗氧化能力，对金属诱导的Aβ聚集的有效抑制作用以及潜在的血脑屏障通透性。化合物7a中展示了在认知和空间记忆显著改善在Aβ 25-35在莫里斯水迷宫测试（MWM）-induce小鼠模型。这些结果表明化合物7a 是一个有前途的多功能候选人，值得进一步研究。
• Phthalazine derivatives as phosphodiesterase 4 inhibitors
  申请人：Zambon Group S.p.A.

  公开号：US06589951B1

  公开（公告）日：2003-07-08

  Compounds of formula (I) wherein B is alkylene, amino, CONH or a bond; Cy is optionally substituted phenyl or heteroaryl; R is H, phenyl or (C1-4)alkyl optionally substituted; R1 is (C1-6)alkyl or polyfluoro(C1-6)-alkyl; R2 is (C4-7)cycloalkyl optionally containing an oxygen atom and optionally substituted; and the N→O derivatives and pharmaceutically acceptable salt thereof are PDE 4 and TNF&agr; inhibitors.

  式（I）中的化合物，其中B是烷基，氨基，CONH或键；Cy是可选择地取代的苯基或杂环芳基；R是H，苯基或（C1-4）烷基可选择地取代；R1是（C1-6）烷基或多氟（C1-6）-烷基；R2是（C4-7）环烷基，可选地含有一个氧原子并可选择地取代；它们的N→O衍生物及其药用可接受的盐是PDE 4和TNF&agr;抑制剂。
• Orally Available Soluble Epoxide Hydrolase/Phosphodiesterase 4 Dual Inhibitor Treats Inflammatory Pain
  作者：René Blöcher、Karen M. Wagner、Raghavender R. Gopireddy、Todd R. Harris、Hao Wu、Bogdan Barnych、Sung Hee Hwang、Yang K. Xiang、Ewgenij Proschak、Christophe Morisseau、Bruce D. Hammock

  DOI：10.1021/acs.jmedchem.7b01804

  日期：2018.4.26

  enhanced analgesic efficacy between soluble epoxide hydrolase (sEH) and phosphodiesterase 4 (PDE4) inhibitors, we designed, synthesized and characterized 21 novel sEH/PDE4 dual inhibitors. The best of these displayed good efficacy in in vitro assays. Further pharmacokinetic studies of a subset of four selected compounds led to the identification of a bioavailable dual inhibitor N-(4-methoxy-2-(tri

  受先前发现的可溶性环氧化物水解酶 (sEH) 和磷酸二酯酶 4 (PDE4) 抑制剂增强镇痛功效的启发，我们设计、合成并表征了 21 种新型 sEH/PDE4 双重抑制剂。其中最好的在体外试验中显示出良好的功效。对四种选定化合物的子集的进一步药代动力学研究导致鉴定出生物可利用的双重抑制剂N -(4-甲氧基-2-(三氟甲基)苄基)-1-丙酰哌啶-4-甲酰胺 ( MPPA )。在脂多糖诱导的炎症性疼痛大鼠模型中，口服 3 mg/kg 后，血液中的MPPA迅速增加（ T max = 30 分钟；C max = 460 nM），并减少炎症疼痛，且起效迅速，与血液水平相关4小时的时间过程。此外，MPPA不会改变患有炎性疼痛的大鼠的自我激励探索或对照大鼠的戒断潜伏期。